Appetite & Cachexia

Overview

Cachexia — the wasting syndrome characterized by involuntary weight loss, muscle atrophy, and anorexia — affects 50–80% of cancer patients and is directly responsible for 20–30% of cancer deaths. AIDS-related wasting was a major cause of morbidity before effective antiretroviral therapy. Both conditions represent significant unmet medical needs.

THC's appetite-stimulating effects are mediated through CB1 receptors in the hypothalamus, particularly in the arcuate nucleus where appetite-regulating neurons are concentrated. THC increases ghrelin (the "hunger hormone") and enhances the hedonic value of food through mesolimbic dopamine pathways — the "munchies" effect has a clear neurobiological basis.

Dronabinol (synthetic THC) received FDA approval for AIDS-related anorexia and weight loss in 1992. The pivotal trial (Beal et al., JAMA 1995, n=139) found dronabinol significantly improved appetite (38% vs. 8% placebo) and stabilized weight in HIV/AIDS patients.

For cancer cachexia, the evidence is more mixed. A 2006 Cancer trial (n=243) comparing cannabis extract, THC, and placebo found no significant difference in appetite or quality of life between groups — a disappointing result. However, a 2011 Journal of Pain and Symptom Management study found dronabinol improved chemosensory perception and appetite in advanced cancer patients.

The discrepancy may reflect the heterogeneity of cancer cachexia — a complex syndrome driven by tumor-derived cytokines that may not respond to appetite stimulation alone. Multimodal approaches combining nutritional support, exercise, and pharmacotherapy may be more effective.